Mr. Speaker, I thank the member for Lotbinière—Chutes-de-la-Chaudière for his speech, in which he listed many aspects of the problem. The only problem I can see is his conclusion. He states that the pharmaceutical industry should be somewhat more co-operative. As it is not, because profit comes first, we are experiencing shortages.
I have a question for my colleague. In view of the fact that pharmaceutical companies will not want to voluntarily discuss their problems—and these are definitely their problems—and they will also not want other companies to know they are having problems, when should reporting no longer be voluntary and measures be imposed to ensure that the patient comes before profit, as my colleague said?